Newton Charles W. (CIK 1866219) reported 11 SEC Form 4 insider transactions across 5 companies over the past 18 months (most recent 2026-06-09). Recent activity: Buy CHRS (30,000 shares), Buy NVAX (9,520 shares), Buy KROS (13,215 shares), Buy LYEL (8,000 shares), Sell LYEL (1,453 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-09 | Coherus Oncology, Inc. (CHRS) | Director | Buy | 30,000 | $0 |
| 2026-04-28 | NOVAVAX INC (NVAX) | Director | Buy | 9,520 | $0 |
| 2026-03-11 | Keros Therapeutics, Inc. (KROS) | Director | Buy | 13,215 | $0 |
| 2025-08-22 | Lyell Immunopharma, Inc. (LYEL) | Chief Financial Officer | Buy | 8,000 | $0 |
| 2025-08-22 | Lyell Immunopharma, Inc. (LYEL) | Chief Financial Officer | Sell | 1,453 | $15,315 |
| 2025-08-13 | Lyell Immunopharma, Inc. (LYEL) | Chief Financial Officer | Sell | 131 | $1,379 |
| 2025-08-13 | Lyell Immunopharma, Inc. (LYEL) | Chief Financial Officer | Sell | 136 | $1,406 |
| 2025-05-15 | 2seventy bio, Inc. (TSVT) | Director | Sell | 17,092 | $0 |
| 2025-05-15 | 2seventy bio, Inc. (TSVT) | Director | Sell | 5,533 | $0 |
| 2025-03-18 | Lyell Immunopharma, Inc. (LYEL) | Chief Financial Officer | Buy | 200,000 | $0 |
| 2025-02-26 | Lyell Immunopharma, Inc. (LYEL) | Chief Financial Officer | Buy | 112,500 | $0 |
Source: SEC Form 4 filings · as of 2026-06-09